Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Hoosier Cancer Research Network
With
OUTLINE: This is a multi-center study. * Rituximab 375 mg/m2 day 1 of 21 day cycle * Gemcitabine 1000 mg/m2 days 1 and 8 of 21 day cycle Subgroup 1. Relapsed after responding to first line chemotherapy, who are not candidates for salvage high-dose chemotherapy. Subgroup 2. Failure to achieve a complete response or relapsed after responding to salvage chemotherapy (any number of salvage regimens allowed), who are not candidates for high-dose chemotherapy. Subgroup 3. Refractory to first line chemotherapy and/or 1 (one) salvage chemotherapy regimen. Subgroup 4. Progression after high-dose chemotherapy. Patients with progressive disease within 3 months of high-dose chemotherapy are not allowed. Performance Status: ECOG performance status 0, 1, 2 Life expectancy: Not specified Hematopoietic:· * ANC ≥ 1,000/mm3· * Platelets ≥ 100,000/mm3 Hepatic:· * Total bilirubin ≤ 2.0 x ULN· * ALT and AST ≤ 3 x ULN unless lymphoma involves the liver on CT scan then AST and ALT can be \< 5 x ULN Renal:· * Serum creatinine ≤ 2.0 mg/dl (except for patients on dialysis) Cardiovascular:· * Not specified Pulmonary:· * Not specified
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
